非何杰金氏淋巴瘤治疗市场：依疗法类型、细胞类型、药物类型、配销通路与地区划分，竞争预测及机会（2020-2030 年预测）

2024年全球非何杰金氏淋巴瘤（NHL）治疗市场规模为81.9亿美元，预计2030年将以7.61%的复合年增长率成长至127.2亿美元。非何杰金氏淋巴瘤（NHL）治疗涵盖一系列旨在控制和对抗这类起源于淋巴系统的血液癌症的医疗手段。这些疗法包括化疗、标靶治疗、免疫疗法、放射疗法和干细胞移植，其目标是清除癌细胞并改善患者预后。

主要市场驱动因素

主要市场挑战

主要市场趋势

目录

第一章：产品概述

第二章：研究方法

第三章：执行概要

第四章：顾客之声

第五章：全球非何杰金氏淋巴瘤（NHL）治疗市场展望

• 市场规模及预测
  • 按价值
• 市占率及预测
  • 依治疗类型（免疫疗法、标靶治疗、化疗、干细胞移植、其他）
  • 依细胞类型（B细胞淋巴瘤、T细胞淋巴瘤）
  • 依药物类型（Revlimid、Rituxan、Keytruda、Imbruvica、Opdivo 等）
  • 按配销通路（医院药房、零售药房、网路药房、其他）
  • 按地区
  • 按公司（2024 年）
• 市场地图

第六章：北美非何杰金氏淋巴瘤（NHL）治疗市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 美国
  • 加拿大
  • 墨西哥

第七章：欧洲非何杰金氏淋巴瘤（NHL）治疗市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区非何杰金氏淋巴瘤（NHL）治疗市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲非何杰金氏淋巴瘤（NHL）治疗市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿联酋
  • 南非

第十章：南美洲非何杰金氏淋巴瘤（NHL）治疗市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章：市场动态

• 司机
• 挑战

第十二章：市场趋势与发展

• 併购（如有）
• 产品发布（如有）
• 最新进展

第十三章：全球非何杰金氏淋巴瘤（NHL）治疗市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商议价能力
• 顾客的力量
• 替代产品的威胁

第十五章：竞争格局

• AstraZeneca PLC
• Baxter International Inc.
• Bayer AG
• Novartis AG
• Eli Lilly and Company.
• Spectrum Pharmaceuticals, Inc.
• Teva Pharmaceutical Industries Ltd.
• Bristol Myers Squibb Company
• GlaxoSmithKline PLC
• Janssen Pharmaceuticals, Inc.

第十六章：策略建议

第17章调查会社について・免责事项

The Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market , valued at USD 8.19 Billion in 2024, is projected to experience a CAGR of 7.61% to reach USD 12.72 Billion by 2030. Non-Hodgkin Lymphoma (NHL) therapeutics comprise a range of medical treatments designed to manage and combat this diverse group of blood cancers originating within the lymphatic system. These therapies, encompassing chemotherapy, targeted therapy, immunotherapy, radiation, and stem cell transplantation, aim to eliminate malignant cells and improve patient outcomes.

Key Market Drivers

Advancements in immunotherapy and CAR T-cell therapies are a primary driver for the Non-Hodgkin Lymphoma therapeutics market, introducing highly effective and specialized treatments. These modalities utilize the patient's immune system or engineered immune cells to precisely target and eliminate cancer cells, offering transformative outcomes for aggressive or refractory NHL. Their increasing adoption, including expansion into earlier lines of treatment, significantly boosts market value. According to Gilead Sciences' full year 2024 financial results, released in February 2025, Cell Therapy product sales, encompassing NHL therapies like Yescarta, increased by 6% to reach $2.0 billion in the full year 2024 compared to 2023, reflecting substantial commercial success and clinical integration.

Key Market Challenges

The high cost associated with advanced therapeutic modalities presents a significant impediment to the growth of the Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market. Modern treatments, particularly immunotherapies, often feature substantial price tags. This directly limits patient access to potentially life-saving or life-extending therapies, especially in healthcare systems with stringent budgetary controls or for individuals with inadequate insurance coverage. Even for patients with coverage, significant out-of-pocket expenses can lead to treatment delays or abandonment, compromising optimal patient outcomes.

Key Market Trends

A significant trend driving the Global Non-Hodgkin Lymphoma therapeutics market is the robust pipeline development and continuous launch of novel drugs. This trend signifies a broader expansion of therapeutic options beyond established categories, addressing diverse patient needs and resistance mechanisms. According to OncLive, almost 20 FDA approvals occurred in the hematology sphere in 2024, demonstrating consistent innovation across blood cancers. This influx of new treatments provides clinicians with more tools to manage the complex and varied subtypes of NHL, including those that are aggressive or refractory.

Key Market Players

• AstraZeneca PLC
• Baxter International Inc.
• Bayer AG
• Novartis AG
• Eli Lilly and Company.
• Spectrum Pharmaceuticals, Inc.
• Teva Pharmaceutical Industries Ltd.
• Bristol Myers Squibb Company
• GlaxoSmithKline PLC
• Janssen Pharmaceuticals, Inc.

Report Scope:

In this report, the Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Non-Hodgkin Lymphoma (NHL) Therapeutics Market , By Type of Therapy:

• Immunotherapy
• Targeted Therapy
• Chemotherapy
• Stem Cell Transplant
• Others

Non-Hodgkin Lymphoma (NHL) Therapeutics Market , By Cell Type:

• B-cell Lymphomas
• T-cell Lymphomas

Non-Hodgkin Lymphoma (NHL) Therapeutics Market , By Drug Type:

• Revlimid
• Rituxan
• Keytruda
• Imbruvica
• Opdivo
• Others

Non-Hodgkin Lymphoma (NHL) Therapeutics Market , By Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Non-Hodgkin Lymphoma (NHL) Therapeutics Market , By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market .

Available Customizations:

Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type of Therapy (Immunotherapy, Targeted Therapy, Chemotherapy, Stem Cell Transplant, Others)
  • 5.2.2. By Cell Type (B-cell Lymphomas, T-cell Lymphomas)
  • 5.2.3. By Drug Type (Revlimid, Rituxan, Keytruda, Imbruvica, Opdivo, Others)
  • 5.2.4. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Others)
  • 5.2.5. By Region
  • 5.2.6. By Company (2024)
• 5.3. Market Map

6. North America Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type of Therapy
  • 6.2.2. By Cell Type
  • 6.2.3. By Drug Type
  • 6.2.4. By Distribution Channel
  • 6.2.5. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type of Therapy
      • 6.3.1.2.2. By Cell Type
      • 6.3.1.2.3. By Drug Type
      • 6.3.1.2.4. By Distribution Channel
  • 6.3.2. Canada Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type of Therapy
      • 6.3.2.2.2. By Cell Type
      • 6.3.2.2.3. By Drug Type
      • 6.3.2.2.4. By Distribution Channel
  • 6.3.3. Mexico Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type of Therapy
      • 6.3.3.2.2. By Cell Type
      • 6.3.3.2.3. By Drug Type
      • 6.3.3.2.4. By Distribution Channel

7. Europe Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type of Therapy
  • 7.2.2. By Cell Type
  • 7.2.3. By Drug Type
  • 7.2.4. By Distribution Channel
  • 7.2.5. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type of Therapy
      • 7.3.1.2.2. By Cell Type
      • 7.3.1.2.3. By Drug Type
      • 7.3.1.2.4. By Distribution Channel
  • 7.3.2. France Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type of Therapy
      • 7.3.2.2.2. By Cell Type
      • 7.3.2.2.3. By Drug Type
      • 7.3.2.2.4. By Distribution Channel
  • 7.3.3. United Kingdom Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type of Therapy
      • 7.3.3.2.2. By Cell Type
      • 7.3.3.2.3. By Drug Type
      • 7.3.3.2.4. By Distribution Channel
  • 7.3.4. Italy Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type of Therapy
      • 7.3.4.2.2. By Cell Type
      • 7.3.4.2.3. By Drug Type
      • 7.3.4.2.4. By Distribution Channel
  • 7.3.5. Spain Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type of Therapy
      • 7.3.5.2.2. By Cell Type
      • 7.3.5.2.3. By Drug Type
      • 7.3.5.2.4. By Distribution Channel

8. Asia Pacific Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type of Therapy
  • 8.2.2. By Cell Type
  • 8.2.3. By Drug Type
  • 8.2.4. By Distribution Channel
  • 8.2.5. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type of Therapy
      • 8.3.1.2.2. By Cell Type
      • 8.3.1.2.3. By Drug Type
      • 8.3.1.2.4. By Distribution Channel
  • 8.3.2. India Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type of Therapy
      • 8.3.2.2.2. By Cell Type
      • 8.3.2.2.3. By Drug Type
      • 8.3.2.2.4. By Distribution Channel
  • 8.3.3. Japan Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type of Therapy
      • 8.3.3.2.2. By Cell Type
      • 8.3.3.2.3. By Drug Type
      • 8.3.3.2.4. By Distribution Channel
  • 8.3.4. South Korea Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type of Therapy
      • 8.3.4.2.2. By Cell Type
      • 8.3.4.2.3. By Drug Type
      • 8.3.4.2.4. By Distribution Channel
  • 8.3.5. Australia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type of Therapy
      • 8.3.5.2.2. By Cell Type
      • 8.3.5.2.3. By Drug Type
      • 8.3.5.2.4. By Distribution Channel

9. Middle East & Africa Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type of Therapy
  • 9.2.2. By Cell Type
  • 9.2.3. By Drug Type
  • 9.2.4. By Distribution Channel
  • 9.2.5. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type of Therapy
      • 9.3.1.2.2. By Cell Type
      • 9.3.1.2.3. By Drug Type
      • 9.3.1.2.4. By Distribution Channel
  • 9.3.2. UAE Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type of Therapy
      • 9.3.2.2.2. By Cell Type
      • 9.3.2.2.3. By Drug Type
      • 9.3.2.2.4. By Distribution Channel
  • 9.3.3. South Africa Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type of Therapy
      • 9.3.3.2.2. By Cell Type
      • 9.3.3.2.3. By Drug Type
      • 9.3.3.2.4. By Distribution Channel

10. South America Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type of Therapy
  • 10.2.2. By Cell Type
  • 10.2.3. By Drug Type
  • 10.2.4. By Distribution Channel
  • 10.2.5. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type of Therapy
      • 10.3.1.2.2. By Cell Type
      • 10.3.1.2.3. By Drug Type
      • 10.3.1.2.4. By Distribution Channel
  • 10.3.2. Colombia Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type of Therapy
      • 10.3.2.2.2. By Cell Type
      • 10.3.2.2.3. By Drug Type
      • 10.3.2.2.4. By Distribution Channel
  • 10.3.3. Argentina Non-Hodgkin Lymphoma (NHL) Therapeutics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type of Therapy
      • 10.3.3.2.2. By Cell Type
      • 10.3.3.2.3. By Drug Type
      • 10.3.3.2.4. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Non-Hodgkin Lymphoma (NHL) Therapeutics Market : SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. AstraZeneca PLC
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Baxter International Inc.
• 15.3. Bayer AG
• 15.4. Novartis AG
• 15.5. Eli Lilly and Company.
• 15.6. Spectrum Pharmaceuticals, Inc.
• 15.7. Teva Pharmaceutical Industries Ltd.
• 15.8. Bristol Myers Squibb Company
• 15.9. GlaxoSmithKline PLC
• 15.10. Janssen Pharmaceuticals, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer